ST6GALNAC3: A Potential Drug Target for Various Diseases (G256435)

Target Name: ST6GALNAC3

NCBI ID: G256435

Other Name(s): ST6GALNAC3 variant 1 | PRO7177 | ST6GALNAC III | ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide alpha-2,6-sialyltran | sialyltransferase 7C | ST6 GalNAc alpha-2,6-sialyltransferase 3 | Sialyltransferase 7 ((alpha-N-acetylneuraminyl-2,3-beta-galactosyl-1,3)-N-acetyl galactosaminide alpha-2,6-sialyltransferase) C | ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 3 | SIA7C_HUMAN | FLJ27239 | FLJ13669 | Alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 3 | ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 3, transcript variant 1 | ST6GALNACIII | sialyltransferase 7 ((alpha-N-acetylneuraminyl-2,3-beta-galactosyl-1,3)-N-acetyl galactosaminide alpha-2,6-sialyltransferase) C | alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase III | Sialyltransferase 7C | ST6GalNAc III | ST6GalNAcIII | STY | Alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 3 (isoform 1) | GalNAc alpha-2,6-sialyltransferase III | SIAT7-C | SIAT7C | Alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase III | ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide alpha-2,6-sialyltransferase 3

ST6GALNAC3: A Potential Drug Target for Various Diseases

ST6GALNAC3 (ST6GALNAC3 variant 1) is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The ST6GALNAC3 gene is a member of the ST6GALNAC3 family, which is known for its role in the development and maintenance of neural stem cells.

Studies have shown that ST6GALNAC3 is involved in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that ST6GALNAC3 is involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, by promoting the production of toxic protein build-up in the brain.

In addition to its involvement in disease, ST6GALNAC3 has also been shown to be a potential drug target. Researchers have identified several potential drug targets for ST6GALNAC3, including its role in the production of toxic protein build-up in the brain. These potential drug targets include the production of neurotransmitters, such as dopamine and glutamate, which are involved in the transmission of signals in the brain, as well as the production of immune cells that are involved in the immune response.

Another potential drug target for ST6GALNAC3 is its role in the regulation of inflammation. Studies have shown that ST6GALNAC3 is involved in the regulation of inflammation in the brain, which is thought to play a role in the development of various autoimmune disorders.

In conclusion, ST6GALNAC3 is a gene that has been identified as a potential drug target or biomarker for various diseases. Its involvement in the development and progression of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders makes it an attractive target for researchers to investigate further. Further studies are needed to fully understand the role of ST6GALNAC3 in disease and to identify effective drug treatments.

Protein Name: ST6 N-acetylgalactosaminide Alpha-2,6-sialyltransferase 3

Functions: Transfers the sialyl group (N-acetyl-alpha-neuraminyl or NeuAc) from CMP-NeuAc to the GalNAc residue on the NeuAc-alpha-2,3-Gal-beta-1,3-GalNAc sequence of glycoproteins and glycolipids forming an alpha-2,6-linkage. Produces branched type disialyl structures by transfer of a sialyl group onto a GalNAc residue inside the backbone core chains. ST6GalNAcIII prefers glycolipids to glycoproteins, predominantly catalyzing the biosynthesis of ganglioside GD1alpha from GM1b (PubMed:16169874, PubMed:17123352). GD1alpha is a critical molecule in the communication and interaction between neuronal cells and their supportive cells, particularly in brain tissues, and functions as an adhesion molecule in the process of metastasis (By similarity). Sialylation of glycoproteins or glycosphingolipids is very important in tumor development, neuronal development, nerve repair, immunological processes and regulation of hormone sensitivity (PubMed:17123352)

More Common Targets